Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,102
  • Shares Outstanding, K 20,946
  • Annual Sales, $ 156,310 K
  • Annual Income, $ -245,760 K
  • 60-Month Beta 1.26
  • Price/Sales 0.72
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AGEN with:

Options Overview Details

View History
  • Implied Volatility 179.58% ( -21.12%)
  • Historical Volatility 111.71%
  • IV Percentile 85%
  • IV Rank 24.31%
  • IV High 615.22% on 11/17/23
  • IV Low 39.67% on 08/14/23
  • Put/Call Vol Ratio 1.35
  • Today's Volume 47
  • Volume Avg (30-Day) 541
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 96,481
  • Open Int (30-Day) 78,327

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -3.10
  • Number of Estimates 4
  • High Estimate -1.60
  • Low Estimate -4.20
  • Prior Year -4.40
  • Growth Rate Est. (year over year) +29.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.78 +18.64%
on 04/18/24
11.83 -52.11%
on 04/01/24
-5.59 (-49.65%)
since 03/19/24
3-Month
4.78 +18.64%
on 04/18/24
18.98 -70.15%
on 02/14/24
-5.90 (-50.99%)
since 01/19/24
52-Week
4.78 +18.64%
on 04/18/24
42.60 -86.70%
on 06/09/23
-30.33 (-84.26%)
since 04/19/23

Most Recent Stories

More News
Down 75%. Is Agenus Stock a Buy on the Dip?

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

RILY : 19.96 (+1.06%)
MRK : 125.16 (-0.06%)
BMY : 48.48 (+0.37%)
GSK : 39.65 (+0.97%)
AGEN : 5.61 (+12.88%)
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?

These stocks could rocket higher, but they also present significant risks.

BMY : 48.48 (+0.37%)
GSK : 39.65 (+0.97%)
RILY : 19.96 (+1.06%)
DNA : 0.9195 (-0.55%)
AGEN : 5.61 (+12.88%)
Agenus (AGEN) Q4 2023 Earnings Call Transcript

AGEN earnings call for the period ending December 31, 2023.

AGEN : 5.61 (+12.88%)
Agenus: Q4 Earnings Snapshot

Agenus: Q4 Earnings Snapshot

AGEN : 5.61 (+12.88%)
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today

The company hopes to engineer a 1-for-20 reverse stock split.

NDAQ : 60.12 (+0.08%)
AGEN : 5.61 (+12.88%)
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

These two biotech stocks could be poised for a trend reversal.

BMY : 48.48 (+0.37%)
AGEN : 5.61 (+12.88%)
CHRS : 1.98 (-1.00%)
Agenus: Q3 Earnings Snapshot

Agenus: Q3 Earnings Snapshot

AGEN : 5.61 (+12.88%)
3 Magnificent Growth Stocks to Buy on the Dip

These three biotech stocks are attractive buys right now.

AGEN : 5.61 (+12.88%)
BCRX : 4.43 (-1.56%)
NNOX : 8.97 (-1.10%)
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 38.11 (+0.79%)
KNSA : 16.71 (-1.01%)
ACAD : 16.95 (-0.70%)
HRMY : 29.16 (+0.45%)
AMPH : 39.02 (+0.96%)
INCY : 52.55 (-0.51%)
AGEN : 5.61 (+12.88%)
NVS : 93.83 (+1.36%)
PFE : 25.75 (+1.42%)
SGEN : 228.74 (-0.07%)
MRK : 125.16 (-0.06%)
RXDX : 199.92 (+0.09%)
Agenus: Q2 Earnings Snapshot

Agenus: Q2 Earnings Snapshot

AGEN : 5.61 (+12.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

3rd Resistance Point 7.18
2nd Resistance Point 6.66
1st Resistance Point 5.81
Last Price 5.61
1st Support Level 4.45
2nd Support Level 3.93
3rd Support Level 3.09

See More

52-Week High 42.60
Fibonacci 61.8% 28.15
Fibonacci 50% 23.69
Fibonacci 38.2% 19.22
Last Price 5.61
52-Week Low 4.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar